Fexigra 120Mg

COMPOSITION

FEXIGRA 120: Each film-coated tablet contains: Fexofenadine Hydrochloride Ph. Eur 120 mg. FEXIGRA 180: Each film-coated tablet contains: Fexofenadine Hydrochloride Ph. Eur 180 mg. 

DESCRIPTION

Fexofenadine, an active metabolite of terfenadine, is a "non-sedating" antihistamine with selective peripheral H1 receptor antagonist activity. Fexofenadine lacks the cardiotoxic potential of terfenadine since it does not block the potassium channel involved in repolarization of cardiac cells. Also, fexofenadine does not possess appreciable anticholinergic, antidopaminergic or α- adrenergic blocking effects at usual antihistaminic doses.  

INDICATIONS

FEXIGRA is indicated for the relief of symptoms associated with allergic rhinitis and allergic skin conditions eg. chronic urticaria. 

CONTRAINDICATIONS

The product is contraindicated in patients with known hypersensitivity to any of its ingredients. 

DRUG INTERACTIONS

Fexofenadine does not undergo hepatic biotransformation and is therefore unlikely to interact with drugs that rely upon hepatic metabolism. Plasma concentrations of fexofenadine have been increased after the concomitant administration of erythromycin or ketoconazole, but unlike, terfenadine, is not associated with adverse effects on the QT interval. Fexofenadine hydrochloride at doses of 120 mg twice daily has been safely Coad ministered with erythromycin (500 mg three times daily) and ketoconazole (400 mg once daily) under steady State conditions in healthy volunteers. Antacids containing aluminum and magnesium hydroxide have reduced the absorption of fexofenadine. 

SIDE EFFECTS

In placebo-controlled trials, which included 2461 patients receiving fexofenadine hydrochloride at doses of 20 mg to 240 mg twice daily, adverse events were similar in fexofenadine hydrochloride and placebo-treated patients. The incidence of adverse events, including drowsiness, was not dose related and was similar across subgroups defined by age, gender, and race. Common: headache. Uncommon: fatigue, drowsiness, nausea, tachycardia, dyspepsia, viral infection and dysmenorrhea. 

OVERDOSAGE

Single doses of fexofenadine hydrochloride up to 800 mg and doses up to 690 mg twice daily for one month were administered without the development of clinically significant adverse effects. In the event of overdose, consider standard measures to remove any unabsorbed drug from the GI tract. Symptomatic and supportive treatment is recommended. 

CIPLA LTD